Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study

Amy Leval, Eva Herweijer, Alexander Ploner, Sandra Eloranta, Julia Fridman Simard, Joakim Dillner, Cecilia Young, Eva Netterlid, Pär Sparén, Lisen Arnheim-Dahlström, Amy Leval, Eva Herweijer, Alexander Ploner, Sandra Eloranta, Julia Fridman Simard, Joakim Dillner, Cecilia Young, Eva Netterlid, Pär Sparén, Lisen Arnheim-Dahlström

Abstract

Background: Incidence of condyloma, or genital warts (GW), is the earliest possible disease outcome to measure when assessing the effectiveness of human papillomavirus (HPV) vaccination strategies. Efficacy trials that follow prespecified inclusion and exclusion criteria may not be fully generalizable to real-life HPV vaccination programs, which target a broader segment of the population. We assessed GW incidence after on-demand vaccination with quadrivalent HPV vaccine using individual-level data from the entire Swedish population.

Methods: An open cohort of girls and women aged 10 to 44 years living in Sweden between 2006 and 2010 (N > 2.2 million) was linked to multiple population registers to identify incident GW in relation to HPV vaccination. For vaccine effectiveness, incidence rate ratios of GW were estimated using time-to-event analyses with adjustment for attained age and parental education level, stratifying on age at first vaccination.

Results: A total of 124 000 girls and women were vaccinated between 2006 and 2010. Girls and women with at least one university-educated parent were 15 times more likely to be vaccinated before age 20 years than girls and women whose parents did not complete high school (relative risk ratio = 15.45, 95% confidence interval [CI] = 14.65 to 16.30). Among those aged older than 20 years, GW rates declined among the unvaccinated, suggesting that HPV vaccines were preferentially used by women at high risk of GW. Vaccination effectiveness was 76% (95% CI = 73% to 79%) among those who received three doses of the vaccine with their first dose before age 20 years. Vaccine effectiveness was highest in girls vaccinated before age 14 years (effectiveness = 93%, 95% CI = 73% to 98%).

Conclusions: Young age at first vaccination is imperative for maximizing quadrivalent HPV vaccine effectiveness.

References

    1. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007; 196(10):1447–1454
    1. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012; 206(6):860–866
    1. Tegnell A, Dillner J, Andrae B. Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveill. 2009; 14(6):19119
    1. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341: c3493.
    1. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011; 105(1):28–37
    1. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928–1943
    1. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102(5):325–339
    1. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011; 11(1):39–44
    1. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Inf. 2011; 87(7):544–547
    1. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Pub Health. 2012; 102(5):833–835
    1. Castle PE, Zhao FH. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs. J Infect Dis. 2011; 204(3):335–337
    1. Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010; 201(11):1607–1610
    1. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659–667
    1. World Health Organization International Classification of Disease, Tenth Revision. Geneva, Switzerland: WHO; 2010.
    1. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Pub Health. 2011; 11: 450.
    1. Munoz N, Manalastas R, Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009; 373(9679):1949–1957
    1. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19):1915–1927
    1. Marlow LA, Waller J, Wardle J. Public awareness that HPV is a risk factor for cervical cancer. Br J Cancer. 2007; 97(5):691–694
    1. Marlow LA, Waller J, Wardle J. Trust and experience as predictors of HPV vaccine acceptance. Hum Vaccin. 2007; 3(5):171–175
    1. Dahlstrom LA Tran TN Lundholm C Young C Sundstrom K Sparen P Attitudes to HPV vaccination among parents of children aged 12–15 years—a population-based survey in Sweden. Int J Cancer. 2010; 126(2):500–507

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel